This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
14 Mar 2011

Sanofi & Regeneron Lung Cancer Trial Suffers Setback

Sanofi-Aventis and partner Regeneron have revealed their non-small cell lung cancer drug aflibercept given with the chemotherapy docetaxel failed to increase overall survival time compared with docataxel alone.

Sanofi-aventis and Regeneron Pharmaceuticals announced last week that their Phase III VITAL trial evaluating the investigational drug aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC) showed that adding aflibercept to the chemotherapy drug docetaxel did not meet the primary endpoint of improvement in overall survival compared with docetaxel plus placebo.
 
The addition of aflibercept to docetaxel demonstrated activity in key secondary endpoints of the study: progression free survival (PFS) and an overall objective response rate (ORR) of 23.3% in the aflibercept arm compared to 8.9% in the placebo arm.

Related News